Resources from the same session
335MO - Prevalence of low muscle mass/sarcopenia in prostate cancer patients undergoing androgen deprivation therapy and association with muscle strength and physical function
Presenter: Dennis Taaffe
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
336MO - A phase II single-arm, open-label trial of pamiparib in metastatic castration-resistant prostate cancer (mCRPC) patients with deleterious germline or somatic BRCA1/2 alterations or homologous recombination deficiency (HRD): Interim analysis of efficacy and safety results
Presenter: Diwei Zhao
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
337MO - Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65–74, and ≥75 years: Post-hoc analysis of randomized phase III CHART trial
Presenter: Xuefeng Qiu
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 335MO, 336MO and 337MO
Presenter: Elena Castro
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
272MO - PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)
Presenter: Zongren Wang
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
273MO - DURANCE: A phase Ib/II study to assess the safety and activity of durvalumab (MEDI4736) in combination with S-488210/S-488211 vaccine in non-muscle invasive bladder cancer
Presenter: Gianmarco Leone
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
274MO - Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
Presenter: Jiwei Huang
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 272MO, 273MO and 274MO
Presenter: Johan Chan
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session: Genitourinary tumours
Resources:
Webcast
275MO - Neoadjuvant sacituzumab govitecan, followed by radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC): Updated interim results of SURE-01 trial
Presenter: Brigida Maiorano
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast